Literature DB >> 1713317

Effect of neurokinin A, substance P and calcitonin gene related peptide in peripheral hyperalgesia in the rat paw.

M Nakamura-Craig1, B K Gill.   

Abstract

The effect of neurokinin A (NKA), substance P (SP) and calcitonin gene-related peptide (CGRP) in peripheral hyperalgesia was studied in rats using a modification of the Randall-Selitto paw test. NKA was 10 times more potent than SP which was 500 times more potent than CGRP in inducing hyperalgesia in the rat paw, suggesting that NKA and SP but not CGRP could have an important role in acute hyperalgesic conditions. Furthermore, sensitization induced by several injections of subthreshold doses of NKA or CGRP suggest that these neuropeptides along with SP could participate as mediators or modulators of chronic pain.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1713317     DOI： 10.1016/0304-3940(91)90819-f

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN： 0304-3940            Impact factor:   3.046


  21 in total

1.  Variable sensitivity to noxious heat is mediated by differential expression of the CGRP gene.

Authors:  Jeffrey S Mogil; Frank Miermeister; Frank Seifert; Kate Strasburg; Katharina Zimmermann; Heiko Reinold; Jean-Sebastien Austin; Nadia Bernardini; Elissa J Chesler; Heiko A Hofmann; Christian Hordo; Karl Messlinger; Kumar V S Nemmani; Andrew L Rankin; Jennifer Ritchie; Angela Siegling; Shad B Smith; Susana Sotocinal; Axel Vater; Sonya G Lehto; Sven Klussmann; Remi Quirion; Martin Michaelis; Marshall Devor; Peter W Reeh
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-23       Impact factor: 11.205

2.  Potential mechanisms for hypoalgesia induced by anti-nerve growth factor immunoglobulin are identified using autoimmune nerve growth factor deprivation.

Authors:  E M Hoffman; Z Zhang; M B Anderson; R Schechter; K E Miller
Journal:  Neuroscience       Date:  2011-07-28       Impact factor: 3.590

3.  Contralateral but not systemic administration of the kappa-opioid agonist U-50,488H induces anti-nociception in acute hindpaw inflammation in rats.

Authors:  I Bileviciute-Ljungar; M Spetea
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 4.  Calcitonin gene-related peptide in the joint: contributions to pain and inflammation.

Authors:  David A Walsh; Paul I Mapp; Sara Kelly
Journal:  Br J Clin Pharmacol       Date:  2015-07-22       Impact factor: 4.335

5.  A comparative study of the ability of calcitonin gene-related peptide and adrenomedullin(13 - 52) to modulate microvascular but not thermal hyperalgesia responses.

Authors:  D Q Chu; M Choy; P Foster; T Cao; S D Brain
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

6.  The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats.

Authors:  Ilaria Cervellini; Ezia Bello; Roberta Frapolli; Carla Porretta-Serapiglia; Norberto Oggioni; Annalisa Canta; Raffaella Lombardi; Francesca Camozzi; Ilaria Roglio; Roberto Cosimo Melcangi; Maurizio D'incalci; Giuseppe Lauria; Pietro Ghezzi; Guido Cavaletti; Roberto Bianchi
Journal:  Neurotox Res       Date:  2009-10-30       Impact factor: 3.911

7.  Neurokinins inhibit low threshold inactivating K+ currents in capsaicin responsive DRG neurons.

Authors:  Adrian Sculptoreanu; Debra E Artim; William C de Groat
Journal:  Exp Neurol       Date:  2009-07-23       Impact factor: 5.330

Review 8.  CGRP in Animal Models of Migraine.

Authors:  Anne-Sophie Wattiez; Mengya Wang; Andrew F Russo
Journal:  Handb Exp Pharmacol       Date:  2019

Review 9.  Calcitonin gene-related peptide: physiology and pathophysiology.

Authors:  F A Russell; R King; S-J Smillie; X Kodji; S D Brain
Journal:  Physiol Rev       Date:  2014-10       Impact factor: 37.312

10.  Early and late contributions of glutamate and CGRP to mechanical sensitization by endothelin-1.

Authors:  Alla Khodorova; Judith Richter; Michael R Vasko; Gary Strichartz
Journal:  J Pain       Date:  2009-07       Impact factor: 5.820
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.